Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 4-amino-n-(1-(3-cyclohexen-1-ylmethyl)-4-piperidyl)-2-ethoxy-5-nitrobenzamide
2. Blaston
3. Cidine
4. Cinitapride Tartrate
1. 66564-14-5
2. Paxapride
3. Cidine
4. Cinitapride [inn]
5. Cinitapride Hydrogen Tartrate
6. 4-amino-n-[1-(cyclohex-3-en-1-ylmethyl)piperidin-4-yl]-2-ethoxy-5-nitrobenzamide
7. R8i97i2l24
8. 66564-14-5 (free Base)
9. Cinitapride (inn)
10. 4-amino-n-(1-(3-cyclohexen-1-ylmethyl)-4-piperidyl)-2-ethoxy-5-nitrobenzamide
11. Cinitaprida
12. Cinitapridum
13. Cinitapridum [inn-latin]
14. Cinitaprida [inn-spanish]
15. Cidin
16. Unii-r8i97i2l24
17. Paxapride (tn)
18. Cinitapride [mi]
19. 96623-56-2
20. Cinitapride [mart.]
21. (non-labelled)cinitapride-d5
22. Cinitapride [who-dd]
23. Schembl476454
24. Chembl2104523
25. Schembl19235643
26. Dtxsid60867232
27. Chebi:135642
28. Bcp04096
29. Hy-b2089
30. Akos015909742
31. Bcp9000531
32. Db08810
33. Bcp0726000107
34. Cs-0017505
35. Ft-0665049
36. D07700
37. Q5121012
| Molecular Weight | 402.5 g/mol |
|---|---|
| Molecular Formula | C21H30N4O4 |
| XLogP3 | 3.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Exact Mass | 402.22670545 g/mol |
| Monoisotopic Mass | 402.22670545 g/mol |
| Topological Polar Surface Area | 113 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 586 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
It is indicated to treat gastrointestinal disorders associated with motility disturbances like gastroesophageal reflux disease (GERD), non-ulcer dyspepsia and delayed gastric emptying.
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
A - Alimentary tract and metabolism
A03 - Drugs for functional gastrointestinal disorders
A03F - Propulsives
A03FA - Propulsives
A03FA08 - Cinitapride
Absorption
The absorption of cinitapride (12mg) following oral administration was rapid, with peak levels being achieved 2 h after dosing; absorption following intramuscular administration (4mg) was even more rapid, with peak levels (50% more that oral levels) being achieved 1 h after dosing.
3-5 h during the first 8 h and a residual half-life greater than 15 h thereafter.
Cinitapride is a substituted benzamide with 5-HT receptor antagonist and agonist activity.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
ABOUT THIS PAGE
93
PharmaCompass offers a list of Cinitapride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cinitapride manufacturer or Cinitapride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cinitapride manufacturer or Cinitapride supplier.
PharmaCompass also assists you with knowing the Cinitapride API Price utilized in the formulation of products. Cinitapride API Price is not always fixed or binding as the Cinitapride Price is obtained through a variety of data sources. The Cinitapride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cinitaprida manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cinitaprida, including repackagers and relabelers. The FDA regulates Cinitaprida manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cinitaprida API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cinitaprida manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cinitaprida supplier is an individual or a company that provides Cinitaprida active pharmaceutical ingredient (API) or Cinitaprida finished formulations upon request. The Cinitaprida suppliers may include Cinitaprida API manufacturers, exporters, distributors and traders.
click here to find a list of Cinitaprida suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Cinitaprida Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cinitaprida GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cinitaprida GMP manufacturer or Cinitaprida GMP API supplier for your needs.
A Cinitaprida CoA (Certificate of Analysis) is a formal document that attests to Cinitaprida's compliance with Cinitaprida specifications and serves as a tool for batch-level quality control.
Cinitaprida CoA mostly includes findings from lab analyses of a specific batch. For each Cinitaprida CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cinitaprida may be tested according to a variety of international standards, such as European Pharmacopoeia (Cinitaprida EP), Cinitaprida JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cinitaprida USP).
